Journal of cardiovascular translational research · 2024
Leukocyte Extracellular Vesicles Predict Progression of Systolic Dysfunction in Heart Failure with Mildly Reduced Ejection Fraction (LYCHEE) - A Prospective, Multicentre Cohort Study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gąsecka Aleksandra, Siniarski Aleksander, Duchnowski Piotr, Stępień Konrad, Błażejowska Ewelina, Gajewska Magdalena, Karaban Kacper, Porębska Kinga, Reda Aleksandra, Rogula Sylwester, Rolek Bartosz, Słupik Dorota, Gozdowska Roksana, Kleibert Marcin, Zajkowska Dominika, Grąt Michał, Grabowski Marcin, Filipiak Krzysztof J, van der Pol Edwin, Nieuwland Rienk
Аннотация
Risk stratification in heart failure with mildly-reduced ejection fraction (HFmrEF) remains challenging. We evaluated the predictive value of advanced glycation end products (AGEs) and plasma concentrations of extracellular vesicles (EVs) for the systolic and diastolic dysfunction progression in HFmrEF patients. Skin AGE accumulation was measured using AGE Reader. Plasma EV concentrations were measured using flow cytometry. Among 74 patients enrolled, 13 (18%) had systolic dysfunction progression and 5 (7%) had diastolic dysfunction progression during 6.5 months follow-up. Leukocyte EVs concentrations were higher in patients with systolic dysfunction progression (p = 0.002) and predicted the progression with 75.0% sensitivity and 58.3% specificity, independent of other clinical variables (OR 4.72, 95% CI 0.99-22.31). Skin AGE levels and concentrations of other EV subtypes were not associated with systolic or diastolic dysfunction progression. Increased leukocyte EVs concentrations are associated with 4.7-fold higher odds of systolic dysfunction progression in HFmrEF patients.
Предметные рубрики MeSH
AgedFemaleHumansMaleMiddle AgedBiomarkersDisease ProgressionExtracellular VesiclesGlycation End Products, AdvancedHeart FailureHeart Failure, SystolicLeukocytesPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsSkinStroke VolumeTime FactorsVentricular Dysfunction, LeftVentricular Function, LeftCohort Studies